Summary of deaths on Study S0325
| Patient no. . | Age at entry, y . | Day of death . | Cause of death . | Remark . |
|---|---|---|---|---|
| Dasatinib 100 mg/d | ||||
| 1 | 90 | 60 | Not specified | Off protocol treatment at day 17 due to treatment-related pulmonary embolism |
| 2 | 55 | 368 | Not specified | Off protocol treatment at day 133 due to relapse from CHR to blast crisis |
| 3 | 69 | 406 | Lung cancer (diagnosed at 10 mo) | Off protocol treatment at day 39 due to neuromotor toxicity |
| 4 | 46 | 472 | Motor vehicle accident | On protocol treatment until death |
| 5 | 68 | 1150 | Congestive heart failure, not related to protocol treatment | On protocol treatment until death |
| 6 | 67 | 1290 | Metastatic bladder cancer | Off protocol treatment at day 944 due to diagnosis of bladder cancer |
| 7 | 40 | 1639 | GVHD from postrelapse stem cell transplantation | Off protocol treatment at day 721 due to relapse from CHR |
| Imatinib 400 mg/d | ||||
| 8 | 50 | 246 | CML | Off protocol treatment at day 134 due to relapse from CHR |
| 9 | 63 | 415 | CML | Off protocol treatment at day 186 due to relapse from CHR |
| 10 | 75 | 961 | Cardiopulmonary arrest, not related to protocol treatment or CML | On protocol treatment until death |
| 11 | 70 | 1126 | Cardiopulmonary arrest, not related to protocol treatment or CML | On protocol treatment until death |
| Patient no. . | Age at entry, y . | Day of death . | Cause of death . | Remark . |
|---|---|---|---|---|
| Dasatinib 100 mg/d | ||||
| 1 | 90 | 60 | Not specified | Off protocol treatment at day 17 due to treatment-related pulmonary embolism |
| 2 | 55 | 368 | Not specified | Off protocol treatment at day 133 due to relapse from CHR to blast crisis |
| 3 | 69 | 406 | Lung cancer (diagnosed at 10 mo) | Off protocol treatment at day 39 due to neuromotor toxicity |
| 4 | 46 | 472 | Motor vehicle accident | On protocol treatment until death |
| 5 | 68 | 1150 | Congestive heart failure, not related to protocol treatment | On protocol treatment until death |
| 6 | 67 | 1290 | Metastatic bladder cancer | Off protocol treatment at day 944 due to diagnosis of bladder cancer |
| 7 | 40 | 1639 | GVHD from postrelapse stem cell transplantation | Off protocol treatment at day 721 due to relapse from CHR |
| Imatinib 400 mg/d | ||||
| 8 | 50 | 246 | CML | Off protocol treatment at day 134 due to relapse from CHR |
| 9 | 63 | 415 | CML | Off protocol treatment at day 186 due to relapse from CHR |
| 10 | 75 | 961 | Cardiopulmonary arrest, not related to protocol treatment or CML | On protocol treatment until death |
| 11 | 70 | 1126 | Cardiopulmonary arrest, not related to protocol treatment or CML | On protocol treatment until death |
CHR indicates complete hematologic response; and CML, chronic myeloid leukemia.